The evaluation of the results in the use of cannabidiol in a child with epileptic seizures

Authors

DOI:

https://doi.org/10.33448/rsd-v12i3.40524

Keywords:

Cannabidiol; Epilepsy; Cerebral palsy.

Abstract

Objective: To investigate whether the use of Cannabidiol in children diagnosed with Cerebral Palsy improves motor function and reduces epileptic seizures associated with this pathology. Methodology: This integrative literature review was carried out by collecting data through searches of studies in the databases: National Library of Medicine National Institutes of Health (PubMed) and Virtual Health Library (BVS). Inclusion criteria will consider original articles, published in online databases in the period between 2017 and 2022, in Portuguese, English and Spanish. The descriptors that were used in this study were “Cerebral Palsy” AND “Cannabidiol”, “Cerebral Palsy” AND “Cannabidiol”, “Cannabidiol” AND “Epilepsy” and “Cannabidiol” AND “Epilepsia”. Results: 13 articles were selected, in which it is possible to show that the use of cannabidiol for the treatment of seizures and motor symptoms in children brings benefits such as the reduction in the frequency of seizures. The results of scientific studies obtained so far on the use of CBD in clinical applications may represent hope for patients who are resistant to all conventional antiepileptic drugs. Conclusion: There is still a scarcity of published data, thus preventing the full recommendation of its use for medicinal purposes in pediatrics in cases of epilepsy.

References

Caraballo, R., Demirdjian, G., Reyes, G., Huaman, M., & Gutierrez, R. (2020). Effectiveness of cannabidiol in a prospective cohort of children with drug-resistant epileptic encephalopathy in Argentina. Seizure: The Journal of the British Epilepsy Association, 80, 75–80. https://doi.org/10.1016/j.seizure.2020.06.005

De Carvalho, C. R., Franco, P. L. C., Eidt, I., Hoeller, A. A., & Walz, R. (2017). Canabinoides E Epilepsia: Potencial Terapêutico Do Canabidiol. Vittalle - Revista de Ciências da Saúde, 29(1), 54–63. https://doi.org/10.14295/vittalle.v29i1.6292

Diretrizes de atenção à pessoa com paralisia cerebral / Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de Ações Programáticas Estratégicas. (2014).

Elliott, J., DeJean, D., Clifford, T., Coyle, D., Potter, B. K., Skidmore, B., Alexander, C., Repetski, A. E., Shukla, V., McCoy, B., & Wells, G. A. (2020). Cannabis-based products for pediatric epilepsy: An updated systematic review. Seizure: The Journal of the British Epilepsy Association, 75, 18–22. https://doi.org/10.1016/j.seizure.2019.12.006

Espinosa-Jovel, C. (2020). Cannabinoides en epilepsia: eficacia clínica y aspectos farmacológicos. Neurología (English Edition), 38(1), 49–55. https://doi.org/10.1016/j.nrl.2020.02.005

Fairhurst, C., Kumar, R., Checketts, D., Tayo, B., & Turner, S. (2020). Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial. Developmental Medicine and Child Neurology, 62(9), 1031–1039. https://doi.org/10.1111/dmcn.14548

Huntsman, R. J., Tang-Wai, R., Alcorn, J., Vuong, S., Acton, B., Corley, S., Laprairie, R., Lyon, A. W., Meier, S., Mousseau, D. D., Newmeyer, D., Prosser-Loose, E., Seifert, B., Tellez-Zenteno, J., Huh, L., Leung, E., & Major, P. (2019). Dosage related efficacy and tolerability of Cannabidiol in Children with treatment-resistant epileptic encephalopathy: Preliminary results of the CARE-E study. Frontiers in Neurology, 10, 716. https://doi.org/10.3389/fneur.2019.00716

Klotz, K. A., Grob, D., Schönberger, J., Nakamura, L., Metternich, B., Schulze-Bonhage, A., & Jacobs, J. (2021). Effect of cannabidiol on interictal epileptiform activity and sleep architecture in children with intractable epilepsy: A prospective open-label study. CNS Drugs, 35(11), 1207–1215. https://doi.org/10.1007/s40263-021-00867-0

Libzon, S., Schleider, L. B.-L., Saban, N., Levit, L., Tamari, Y., Linder, I., Lerman-Sagie, T., & Blumkin, L. (2018). Medical cannabis for pediatric moderate to severe complex motor disorders. Journal of Child Neurology, 33(9), 565–571. https://doi.org/10.1177/0883073818773028

Matos, R. L., Spinola, L. A., Barboza, L. L., Garcia, D. R., França, T. C., & Affonso, R. S. (2017). O uso do canabidiol no tratamento da epilepsia. Revista Virtual de Química, 9(2), 786–814.

Michael-Asalu, A., Taylor, G., Campbell, H., Lelea, L.-L., & Kirby, R. S. (2019). Cerebral palsy: Diagnosis, epidemiology, genetics, and clinical update. Advances in Pediatrics, 66, 189–208. https://doi.org/10.1016/j.yapd.2019.04.002

Mitelpunkt, A., Kramer, U., Hausman Kedem, M., Zilbershot Fink, E., Orbach, R., Chernuha, V., Fattal-Valevski, A., Deutsch, L., Heffetz, D., & Sacks, H. (2019). The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study. Epilepsy & Behavior: E&B, 98(Pt A), 233–237. https://doi.org/10.1016/j.yebeh.2019.07.007

Oshiro, C. A., & Castro, L. H. M. (2022). Cannabidiol and epilepsy in Brazil: a current review. Arquivos de Neuro-Psiquiatria, 80(5 Suppl 1), 182–192. https://doi.org/10.1590/0004-282X-ANP-2022-S137

Patel, D. R., Neelakantan, M., Pandher, K., & Merrick, J. (2020). Cerebral palsy in children: a clinical overview. Translational Pediatrics, 9(Suppl 1), S125–S135. https://doi.org/10.21037/tp.2020.01.01

Pernoncini, K. V., & Oliveira, R. M. M. (2014). Usos Terapêuticos Potenciais Do Canabidiol Obtido Da Cannabis sativa. Uningá Review, 20(3). https://revista.uninga.br/uningareviews/article/view/1609

Pesantez-Rios, G., Armijos-Acurio, L., Jimbo-Sotomayor, R., Pascual-Pascual, S. I., & Pesantez-Cuesta, G. (2017). Cannabidiol: its use in refractory epilepsies. Revista de neurologia, 65(4), 157–160.

Scheffer, I. E., Hulihan, J., Messenheimer, J., Ali, S., Keenan, N., Griesser, J., Gutterman, D. L., Sebree, T., & Sadleir, L. G. (2021). Safety and tolerability of transdermal cannabidiol gel in children with developmental and epileptic encephalopathies: A nonrandomized controlled trial: A nonrandomized controlled trial. JAMA Network Open, 4(9), e2123930. https://doi.org/10.1001/jamanetworkopen.2021.23930

Schier, A. R. de M., Ribeiro, N. P. de O., Silva, A. C. de O. e., Hallak, J. E. C., Crippa, J. A. S., Nardi, A. E., & Zuardi, A. W. (2012). Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Revista Brasileira de Psiquiatria (Sao Paulo, Brazil: 1999), 34 Suppl 1, S104-10. https://doi.org/10.1590/s1516-44462012000500008

Sheffali. (2018). Cerebral palsy: an overview. The Indian Journal of Pediatrics, 11, 1006–1016.

Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., & Mazzon, E. (2019). Use of cannabidiol in the treatment of epilepsy: Efficacy and security in clinical trials. Molecules (Basel, Switzerland), 24(8), 1459. https://doi.org/10.3390/molecules24081459

Szaflarski, J. P., Bebin, E. M., Cutter, G., DeWolfe, J., Dure, L. S., Gaston, T. E., Kankirawatana, P., Liu, Y., Singh, R., Standaert, D. G., Thomas, A. E., Ver Hoef, L. W., & UAB CBD Program. (2018). Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy & Behavior: E&B, 87, 131–136. https://doi.org/10.1016/j.yebeh.2018.07.020

Williams, C. M., & Stephens, G. J. (2020). Development of cannabidiol as a treatment for severe childhood epilepsies. British Journal of Pharmacology, 177(24), 5509–5517. https://doi.org/10.1111/bph.15274

Published

25/02/2023

How to Cite

JESUS, L. V. de .; COSTA, M. M. .; GONZALES, M. H.; MARCELINO NETO, O. J. . The evaluation of the results in the use of cannabidiol in a child with epileptic seizures. Research, Society and Development, [S. l.], v. 12, n. 3, p. e7712340524, 2023. DOI: 10.33448/rsd-v12i3.40524. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/40524. Acesso em: 12 oct. 2024.

Issue

Section

Health Sciences